Rx00076 - Cysteamine Hydrochloride


Name:
Cysteamine Hydrochloride
Rx ID:
Rx00076
Validation Level:
Phenomic Similarity:
0.577
Reference ID:
DB00847
Primary Indications:
Corneal cystine crystal accumulation; cystinosis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Corneal cystine crystal accumulation; cystinosis patients; Huntington's disease; neuronal ceroid lipofuscinoses; Batten disease
Common Indications:
Adult nephropathic cystinosis; juvenile nephropathic cystinosis
Drug Interactions:
No annotated drug interactions in DrugBank.
Food Interactions:
Avoid administration of delayed release cysteamine less than 30 minutes before and within 2 hours after ingesting food due to decreased bioavailability of cysteamine.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00076
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Chemical, Pharmacological and Biological Annotations


ATC Code:
A16AA04
Brand:
Procysbi (Raptor Pharms)
Categories:
Radiation-Protective Agents; Ophthalmics
ChEBI ID:
17141
PubChem ID:
6058
KEGG Drug ID:
D03634
SMILE:
NCCS
InChI:
1S/C2H7NS/c3-1-2-4/h4H,1-3H2
Classification:
Kingdom:
Organic Compounds
Superclass:
Organonitrogen Compounds
Class:
Amines
Subclass:
Polyamines
Indication:
Given intravenously or orally to treat radiation sickness. The bitartrate salts (Cystagon® and Procysbi) have been used for the oral treatment of nephropathic cystinosis and cystinurea. The hydrochloride salt (Cystaran™) is indicated for th...
Click to show more...
Pharmacodynamics:
People born without the ability to metabolize the amino acid cystine suffer from cystinosis, a rare inherited disorder characterized by the deposition and accumulation of cystine crystals throughout the body. These crystals cause considerab...
Click to show more...
Description:
Cysteamine is a radiation-protective agent that oxidizes in air to form cystamine. It can be given intravenously or orally to treat radiation sickness. The bitartrate and hydrochloride salt forms are indicated for the treatment of neuropath...
Click to show more...
Mechanism:
The free thiol cysteamine depletes cystinotic leukocytes and other cells of cystine, whose accumulation is considered the cause of organ damage in cystinosis. Cysteamine cleaves the disulfide bond with cystine to produce molecules that can ...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
+
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.2165 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org